SillaJen's next-generation oncology pipeline candidate BAL0891 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML). (BigGo) - Aug 24, 2026 - "BAL0891 is a first-in-class anti-cancer drug candidate that simultaneously targets TTK and PLK1, two key proteins involved in cancer cell division, and is currently in global Phase 1 clinical trials for both solid tumors and hematologic malignancies."
Orphan drug • Acute Myelogenous Leukemia
|